How do you take BPC-157 peptide? routes, and what studies show

Last updated 2026-07-24

What routes of administration has BPC-157 actually been studied by?

Three routes show up in the published literature: injection (subcutaneous, intramuscular, or intraperitoneal), oral dosing mixed into drinking water, and local injection directly into a joint or tissue site. The overwhelming majority of this work is in rats and mice. A 2019 review in Cell and Tissue Research describes BPC-157 accelerating healing of tendon, ligament, muscle, and other soft tissue in animal models, using injected and topically applied peptide in surgical injury models ^[1]. A 2018 review in Current Pharmaceutical Design covers similar ground, comparing BPC-157's effects on angiogenesis and tissue repair to standard growth factors, again almost entirely in animal tissue and GI healing models ^[2]. The one route with real human data is intra-articular injection, meaning injection directly into a joint. A small pilot study published in Alternative Therapies in Health and Medicine in 2021 gave BPC-157 by intra-articular injection to patients with knee pain from different causes and reported symptom improvement ^[3]. That is a genuinely human data point, but it's a pilot study, not a large randomized trial, and it does not tell you anything about oral dosing or subcutaneous injection at home. No route, dose, or schedule for BPC-157 has been established through an FDA-reviewed clinical trial. Anything you read presented as a 'standard protocol' is extrapolated from these small studies or from vendor material, not from regulatory-grade human evidence.

Is BPC-157 taken by injection, orally, or both?

Both, depending on what's being studied, and the two routes are not interchangeable in the data. Subcutaneous and intramuscular injection are the routes used in most of the tendon, ligament, and muscle healing studies in rodents. A 2011 study in the Journal of Applied Physiology looked at how BPC-157 promotes tendon healing at the cellular level, examining tendon outgrowth, cell survival, and cell migration in explant and animal models, using injected peptide ^[4]. Oral administration, BPC-157 dissolved in drinking water, shows up mainly in the gastrointestinal healing literature, where the peptide's origin as a "body protection compound" derived from gastric juice made oral testing a logical starting point in animal models ^[2]. Some of this oral rodent work reports effects on gut lesions, fistulas, and ulcers that survive stomach exposure, which is part of why BPC-157 built a reputation as unusually stable compared to other peptides. Here's the honest gap: nobody has published human pharmacokinetic data comparing oral versus injected BPC-157 in people. We don't have absorption numbers, bioavailability percentages, or half-life data from human trials for either route. If you see a specific bioavailability percentage quoted online, ask where it came from. In most cases it traces back to animal data or isn't sourced at all.

What does BPC-157 dosing look like in the animal studies?

Animal studies use doses expressed in micrograms per kilogram of body weight, injected into rats or mice, and these numbers cannot be converted into a human dose by simple math. This matters enough to repeat: a dose that worked in a 300-gram rat tells you about that rat's biology, not about a 180-pound adult. Species differ in metabolism, body surface area to weight ratios, and drug clearance rates, which is why regulatory dose-conversion formulas exist in the first place and why they still don't substitute for an actual human trial. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled 'Regeneration or Risk?', looks specifically at this gap, weighing the musculoskeletal healing signal in preclinical work against how little of it has been tested in controlled human studies ^[5]. A 2025 literature and patent review in Pharmaceuticals covers the range of doses and models used across the BPC-157 literature, spanning wound healing, GI protection, and musculoskeletal applications, and it is worth reading precisely because it shows how scattered the dosing data actually is across studies with different animals, injury models, and endpoints ^[6]. There is no single dose that the field has converged on, because there is no single confirmatory human trial that dosing would be based on. If you want the deeper breakdown of what animal-study numbers mean and don't mean for a person, that's covered on our bpc 157 dosage page, and if you're trying to work out volumes from a vial, the bpc 157 dosage calculator walks through the math (again, using research-based reference points, not a validated human protocol).

How is BPC-157 injected in the research that exists?

In animal studies, injection is typically subcutaneous (under the skin) or intramuscular (into muscle), sometimes intraperitoneal (into the abdominal cavity) for systemic effect, and occasionally intra-articular for direct joint delivery. The one human study using injection was intra-articular, meaning delivered by a clinician directly into the knee joint, not a self-administered subcutaneous shot ^[3]. That distinction matters because it changes what the study actually demonstrates. Intra-articular injection puts the peptide at the site of joint pathology under sterile clinical conditions with a needle placed by a trained provider. It says nothing about what happens when BPC-157 is injected subcutaneously at home, which is how it is most often discussed online. A 2025 systematic review in the HSS Journal (Hospital for Special Surgery) looked specifically at BPC-157 use in orthopaedic sports medicine, reviewing the literature on tendon, ligament, and joint applications, and it flags this same pattern: most mechanistic and efficacy data is preclinical, while human orthopedic use remains limited to small studies and case reports ^[7]. Our bpc 157 peptide injections page covers injection technique and site selection questions people commonly have, again framed around what's actually documented rather than a settled clinical protocol.

Can BPC-157 be taken orally instead of injected?

Oral BPC-157 has been tested in animal studies, mainly for gut-related outcomes, but there is no published human trial establishing that an oral dose reaches tissue or produces the effects seen with injection. The peptide's discovery narrative, as a stable fragment derived from human gastric juice, is part of why researchers tested oral dosing in rodent GI models in the first place, reasoning that a gut-protective compound ought to survive gut transit ^[2]. Some animal data supports that survival. What's missing is human confirmation that an orally dosed peptide crosses into systemic circulation at levels comparable to injection, or that it reaches a healing tendon or ligament the way injected peptide might in a rat model. A 2026 primer in The American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians navigating injectable peptide therapies, discusses route of administration as one of the open questions clinicians face with BPC-157 and similar compounds, since so much of the mechanistic case is built on injected-peptide animal data rather than oral human pharmacokinetics ^[8]. If your interest is specifically musculoskeletal injury (tendon, ligament, joint), the published research is overwhelmingly about injected peptide in animal injury models, not an oral capsule taken for the same purpose.

How often is BPC-157 dosed in the studies (once daily, twice, cycled)?

Animal protocols vary a lot: some studies dose once daily, others use twice-daily injections over a period of days to weeks, timed to the injury model being tested. There is no human dosing schedule that has been validated in a trial. Because each rodent study is designed around a specific injury (a cut tendon, a chemically induced ulcer, a transected muscle) and a specific endpoint (tensile strength at day 14, lesion size at day 7), dosing frequency in the literature tracks the experimental design, not a general 'how to take it' answer. That's a structural feature of preclinical pharmacology research, and it means you can't lift a frequency number from one rat study and assume it applies broadly, let alone to a human. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, covering therapeutic peptides in orthopaedics generally, notes this same challenge across the peptide class: promising mechanistic and animal data paired with a thin and inconsistent human dosing record, which makes cross-study comparison difficult even within the animal literature ^[9]. Anyone telling you there's a settled 'cycle' (two weeks on, two off, or similar) is passing along a convention that did not originate from a human clinical trial.

What does the human evidence say about BPC-157 dosing and effect?

Human data on BPC-157 is small, early, and mostly limited to two published studies: an intra-articular knee pain pilot and an interstitial cystitis pilot. Neither establishes a general dosing protocol. The knee pain study, published in Alternative Therapies in Health and Medicine in 2021, examined intra-articular BPC-157 injection across patients with different underlying causes of knee pain and reported symptomatic improvement ^[3]. It is described in the literature as a pilot study, meaning small sample size and no long-term controlled follow-up in the way a phase 2 or 3 trial would provide. The second is a 2024 pilot study, also in Alternative Therapies in Health and Medicine, looking at BPC-157's effect on symptoms in patients with interstitial cystitis (a chronic bladder pain condition), again a small trial exploring a specific administration and symptom outcome rather than a dose-ranging study ^[10]. That's the entire specific human clinical record behind BPC-157 as of the current literature: two small pilot studies, different conditions, different endpoints, neither designed to answer 'what is the right dose for a healthy person recovering from a strain.' Everything else you'll find framed as a human protocol is inference from these two pilots plus a much larger animal literature, or it's simply unsourced.

Does the route of administration change how safe BPC-157 is?

Nobody has published a controlled human trial directly comparing safety across oral, subcutaneous, and intra-articular BPC-157, so no one can tell you with confidence that one route is meaningfully safer than another in people. What is published are safety signals from animal work and a caution flag from recent review authors about the imbalance between preclinical promise and human safety data. The 2025 'Regeneration or Risk?' narrative review in Current Reviews in Musculoskeletal Medicine specifically frames its title around this tension, examining musculoskeletal healing claims against the actual human safety and efficacy record ^[5]. A 2026 review in Sports Medicine (Auckland) looking at safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance places BPC-157 among peptides used off-label with limited controlled human safety data behind them ^[11]. A related consideration: BPC-157's proposed mechanism involves promoting blood vessel growth (angiogenesis). A 2014 review in Current Pharmaceutical Design covers BPC-157's documented effects on blood vessels in animal models, describing a pro-angiogenic effect that is part of the proposed healing mechanism ^[12]. Pro-angiogenic activity is exactly the kind of effect that deserves real scrutiny in anyone with a history of cancer, since tumor growth also depends on new blood vessel formation, and this has not been ruled out or ruled in by human trial data either way. If side effects and drug interactions are your main concern before choosing a route, the bpc 157 peptide side effects page goes through what's reported.

Is BPC-157 legal to buy and take in the United States?

BPC-157 is not FDA-approved for any use in humans, and it does not appear on either FDA bulks list that allows a compounding pharmacy to use a substance in human compounded prescriptions. That is a specific regulatory fact worth understanding before deciding how, or whether, to obtain it. Under federal law, pharmacies compounding drugs for individual patients operate under 21 U.S.C. 353a, and the substances they're permitted to use for human compounding are governed by lists FDA maintains under 21 CFR 216.23 (the 503A bulks list) ^[13] and 21 CFR 216.24 (the 503B bulks list) ^[14]. FDA's own guidance page on bulk drug substances used in compounding under section 503A explains this framework directly ^[15]. BPC-157 has been nominated for inclusion but, as of the most recent FDA nominated-substances list, is not on the approved bulks list, which means it sits in a gray zone: not an approved drug, not a lawfully compoundable bulk substance either, per FDA's published nomination list ^[16]. You will not find BPC-157 in FDA's Drugs@FDA database of approved drug products, because it has never gone through that approval process ^[17]. Anyone selling it as a supplement, or marketing specific medical claims about it, is operating outside what current FDA rules recognize. That doesn't mean nothing legitimate exists in this space, but it does mean the regulatory status is unsettled, and buying from an unverified source carries real quality and legal uncertainty on top of the open efficacy questions. Our bpc 157 for sale page walks through the sourcing landscape in more detail.

What should you actually do if you're considering BPC-157?

Talk to a physician who knows the literature, understand that you'd be acting on preclinical rodent data plus two small human pilot studies, and if you decide to move forward, do it through a provider who reviews your case rather than a source with no clinical oversight. That's not a dodge. It's the honest state of the evidence. A 2025 review in Arthroscopy covers injectable therapeutic peptides broadly as a possible adjunct to regenerative medicine and sports performance, and even a review written to be optimistic about the category is careful to flag that clinical evidence trails the preclinical enthusiasm substantially ^[18]. The same tension shows up across nearly every recent review cited here: strong mechanistic story in animal models, thin and early human data, no FDA approval, no settled dosing protocol. Where BPC-157 Co fits into this picture: we don't compound or sell peptide. When readers want the provider-reviewed route rather than an unregulated vendor, our role is pointing toward physician oversight and dispensing through a licensed compounding pharmacy partner, which at least puts a clinician and pharmacy quality standards between you and the injection. That's a meaningfully different position than ordering a vial online with no medical review attached, though it still does not turn animal data into a validated human protocol. If you're earlier in your research, start with the bpc 157 peptide overview for the full study record, then the bpc 157 dosage page for how animal doses get (mis)translated into human discussions.

Frequently asked questions

How do you take BPC-157 peptide?

In published research, BPC-157 has been given by subcutaneous or intramuscular injection, orally in drinking water (mostly in animal GI studies), and by intra-articular injection in one small human knee pilot study. There is no FDA-approved or clinically validated 'correct' way to take it in humans, so treat any specific protocol you see online as unverified.

Is BPC-157 taken by injection or orally?

Both routes appear in the literature, but for different purposes. Injection (subcutaneous, intramuscular, intra-articular) dominates the musculoskeletal healing research. Oral dosing shows up mostly in gastrointestinal animal studies. No human trial has directly compared bioavailability or effect between the two routes.

What is the standard human dose of BPC-157?

There isn't one. No clinical trial has established a standard human dose. Animal studies use microgram-per-kilogram dosing in rats and mice, which doesn't translate directly to a human dose. The two published human pilot studies (knee pain and interstitial cystitis) used intra-articular or other clinician-administered protocols, not a general self-dosing standard.

Can you take BPC-157 orally for tendon or ligament healing?

Oral BPC-157 research is concentrated in gastrointestinal healing models in animals, not tendon or ligament studies, which mostly used injection. There's no published human data on oral dosing for tendon or ligament injuries specifically, so any claim about oral effectiveness for these injuries is extrapolation, not documented evidence.

How often should BPC-157 be injected?

Animal studies use varying schedules, from once daily to twice daily, depending on the injury model. No frequency has been validated in human trials. Frequency claims you see online (like specific cycling schedules) are conventions, not findings from a clinical study.

Is BPC-157 FDA approved?

No. BPC-157 does not appear in FDA's Drugs@FDA database of approved products, and it is not on either FDA bulks list (21 CFR 216.23 or 216.24) that would permit its use in compounded human prescriptions, per FDA's current nominated substances list.

What human studies exist for BPC-157?

Two small pilot studies make up the specific human clinical record found in the literature reviewed here: a 2021 intra-articular knee pain study and a 2024 interstitial cystitis pilot, both published in Alternative Therapies in Health and Medicine. Both are small and early, not large randomized controlled trials.

Is BPC-157 safe to inject subcutaneously at home?

No controlled human trial has evaluated at-home subcutaneous injection safety specifically. Recent reviews describe the human safety record as limited relative to the animal literature, and flag open questions including BPC-157's pro-angiogenic (blood vessel-promoting) mechanism, which hasn't been ruled out as a concern in people with a cancer history.

Does BPC-157 work for knee pain?

A small 2021 pilot study using intra-articular injection reported symptom improvement in patients with knee pain from multiple causes. This is one small study, not a large trial, so it suggests a signal worth further research rather than a confirmed treatment effect.

Why is most BPC-157 research done in animals instead of humans?

BPC-157 isn't FDA-approved, so it hasn't gone through the standard human clinical trial pipeline that approved drugs use. Most mechanistic and efficacy research is preclinical (rat and mouse models) because that's where the compound's development has stayed, with only a couple of small human pilot studies published so far.

Can BPC-157 doses from rat studies be converted to a human dose?

Not reliably by simple math. Species differ in metabolism and clearance, and no validated conversion has been confirmed by a human trial for BPC-157 specifically. Micrograms-per-kilogram figures from rodent studies describe that animal's response, not a proven safe or effective human amount.

Where can you legally get BPC-157 in the US?

Because BPC-157 isn't on FDA's approved bulks lists, sourcing sits in a regulatory gray area. The more accountable path is through a physician who reviews your case and dispenses through a licensed compounding pharmacy, rather than an unregulated online vendor with no clinical oversight or quality verification.

Sources

1. Cell and Tissue Research, 2019 (PMID 30915550): BPC-157 accelerates musculoskeletal soft tissue healing (tendon, ligament, muscle) in animal injury models using injected and topical peptide.
2. Current Pharmaceutical Design, 2018 (PMID 29998800): BPC-157's angiogenic effects and role in GI tract healing have been studied largely via oral and injected dosing in animal models.
3. Alternative Therapies in Health and Medicine, 2021 (PMID 34324435): A pilot study gave BPC-157 by intra-articular injection to patients with multiple types of knee pain and reported symptomatic improvement.
4. Journal of Applied Physiology, 2011 (PMID 21030672): BPC-157 promotes tendon healing via tendon outgrowth, cell survival, and cell migration, studied via injected peptide in animal/explant models.
5. Current Reviews in Musculoskeletal Medicine, 2025 (PMID 40789979): A narrative review weighs BPC-157's musculoskeletal healing evidence against the limited human safety and efficacy data available.
6. Pharmaceuticals (Basel), 2025 (PMID 40005999): A literature and patent review documents the range of doses and models used across BPC-157 studies spanning wound healing, GI, and musculoskeletal applications.
7. HSS Journal, 2025 (PMID 40756949): A systematic review of BPC-157 in orthopaedic sports medicine finds most efficacy data is preclinical with limited human studies and case reports.
8. The American Journal of Sports Medicine, 2026 (PMID 41476424): A physician primer on injectable peptide therapy discusses route of administration as an open question for BPC-157 and similar peptides.
9. JAAOS Global Research & Reviews, 2026 (PMID 41490200): A review of therapeutic peptides in orthopaedics notes inconsistent dosing records across the peptide class, making cross-study comparison difficult.
10. Alternative Therapies in Health and Medicine, 2024 (PMID 39325560): A pilot study examined BPC-157's effect on symptoms in patients with interstitial cystitis.
11. Sports Medicine (Auckland), 2026 (PMID 41966639): A review of approved and unapproved peptide therapies for musculoskeletal injuries places BPC-157 among off-label peptides with limited controlled human safety data.
12. Current Pharmaceutical Design, 2014 (PMID 23782145): BPC-157 has documented pro-angiogenic (blood vessel-promoting) effects in animal models, part of its proposed healing mechanism.
13. 21 U.S.C. 353a, pharmacy compounding statute: Federal law governing pharmacy compounding for individual patients.
14. 21 CFR 216.24, the 503B Bulks List: Defines the list of bulk drug substances permitted for use by 503B outsourcing facilities.
15. FDA, bulk drug substances used in compounding under section 503A: FDA guidance explains the framework for which bulk substances pharmacies may use in 503A compounding.
16. FDA, bulk drug substances nominated for use in compounding (current list): BPC-157 has been nominated for the compounding bulks list but is not currently on FDA's approved list.
17. Drugs@FDA, FDA-approved drug products database: BPC-157 does not appear in FDA's database of approved drug products.
18. Arthroscopy, 2025 (PMID 39265666): A review of injectable therapeutic peptides as a possible adjunct to regenerative medicine notes clinical evidence trails preclinical findings.